ArticleBMC neurology2018
Tacrolimus-induced parkinsonism in a patient after liver transplantation - case report.
Article in BMC neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Tacrolimus-Associated Adverse Effects After Liver Transplantation: A Narrative Review.Journal of clinical medicine · 2026Review
- Balancing Graft Survival and Neural Outcomes: Insights From a Systematic Review of Tacrolimus-Induced Neurotoxicity.Cureus · 2025Review
- Neurotoxicity of Calcineurin Inhibitors.Annals of Indian Academy of Neurology · 2025Article
- Tacrolimus-induced Parkinsonism.Journal of neurology · 2024Article
- Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review.Drug safety · 2024Review
- Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic.Therapeutics and clinical risk management · 2022Review
- Movement Disorders and Liver Disease.Movement disorders clinical practice · 2021Review
- Reversible Parkinsonism caused by Influenza B-associated encephalitis affecting bilateral basal ganglia: A case report.CNS neuroscience & therapeutics · 2020Article
- Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities.International journal of molecular sciences · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic encephalopathy may manifest by a wide spectrum of neuropsychiatric symptoms, including cognitive impairment, seizures or extrapyramidal symptoms. The liver transplant can lead to improvement of the signs of encephalopathy but subsequent immunosuppressive treatment might possess pronounced neurotoxicity. CASE PRESENTATION: We present a case report of a patient with chronic liver disease who developed signs of Parkinsonism after an orthotopic liver transplant, with consecutive immunosuppressant treatment with tacrolimus. Despite the improvement of liver functions due to the cytostatic treatment, a progressive worsening of neuropsychiatric symptoms associated with the presence of tremor was observed. Metabolic as well as endocrine dysfunctions were excluded as the primary causes of this condition. A brain CT did not reveal structural pathology. Signs of severe, symmetric Parkinsonism - with resting tremor, bradykinesia, rigidity and severe postural instability were observed. A brain MRI was performed with the presence of T2- hyperintensities in basal ganglia bilaterally. Tacrolimus blood concentration was elevated; hence the dose was reduced and later switched to less toxic sirolimus. Subsequently, clinical signs markedly improved after treatment modification. Improvement of clinical symptomatology after tacrolimus discontinuation supports the drug-induced etiology of this neurological condition.
conclusionsCytostatic treatment after solid organ transplantation often leads to signs of encephalopathy. If necessary, the dose of cytostatics needs to be reduced, or a less toxic agent must be chosen for the therapy. This modification is usually efficient with no further need for neurological intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.